Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT

<strong>Trial design<br></strong> A randomised, parallel-group, double-blind, placebo-controlled multicentre study with health economic and nested qualitative studies to determine if mifepristone (Mifegyne®, Exelgyn, Paris, France) plus misoprostol is superior to misoprostol alone...

ver descrição completa

Detalhes bibliográficos
Principais autores: Devall, A, Chu, J, Beeson, L, Hardy, P, Cheed, V, Sun, Y, Roberts, T, Ogwulu, CO, Williams, E, Jones, L, Papadopoulos, JLF, Bender-Atik, R, Brewin, J, Hinshaw, K, Choudhary, M, Ahmed, A, Naftalin, J, Nunes, N, Oliver, A, Izzat, F, Bhatia, K, Hassan, I, Jeve, Y, Hamilton, J, Deb, S, Bottomley, C, Ross, J, Watkins, L, Underwood, M, Cheong, Y, Kumar, C, Gupta, P, Small, R, Pringle, S, Hodge, F, Shahid, A, Gallos, I, Horne, A, Quenby, S, Coomarasamy, A
Formato: Journal article
Idioma:English
Publicado em: NIHR Journals Library 2021
_version_ 1826260168524955648
author Devall, A
Chu, J
Beeson, L
Hardy, P
Cheed, V
Sun, Y
Roberts, T
Ogwulu, CO
Williams, E
Jones, L
Papadopoulos, JLF
Bender-Atik, R
Brewin, J
Hinshaw, K
Choudhary, M
Ahmed, A
Naftalin, J
Nunes, N
Oliver, A
Izzat, F
Bhatia, K
Hassan, I
Jeve, Y
Hamilton, J
Deb, S
Bottomley, C
Ross, J
Watkins, L
Underwood, M
Cheong, Y
Kumar, C
Gupta, P
Small, R
Pringle, S
Hodge, F
Shahid, A
Gallos, I
Horne, A
Quenby, S
Coomarasamy, A
author_facet Devall, A
Chu, J
Beeson, L
Hardy, P
Cheed, V
Sun, Y
Roberts, T
Ogwulu, CO
Williams, E
Jones, L
Papadopoulos, JLF
Bender-Atik, R
Brewin, J
Hinshaw, K
Choudhary, M
Ahmed, A
Naftalin, J
Nunes, N
Oliver, A
Izzat, F
Bhatia, K
Hassan, I
Jeve, Y
Hamilton, J
Deb, S
Bottomley, C
Ross, J
Watkins, L
Underwood, M
Cheong, Y
Kumar, C
Gupta, P
Small, R
Pringle, S
Hodge, F
Shahid, A
Gallos, I
Horne, A
Quenby, S
Coomarasamy, A
author_sort Devall, A
collection OXFORD
description <strong>Trial design<br></strong> A randomised, parallel-group, double-blind, placebo-controlled multicentre study with health economic and nested qualitative studies to determine if mifepristone (Mifegyne®, Exelgyn, Paris, France) plus misoprostol is superior to misoprostol alone for the resolution of missed miscarriage. <br><strong> Methods<br></strong> Women diagnosed with missed miscarriage in the first 14 weeks of pregnancy were randomly assigned (1 : 1 ratio) to receive 200 mg of oral mifepristone or matched placebo, followed by 800 μg of misoprostol 2 days later. A web-based randomisation system allocated the women to the two groups, with minimisation for age, body mass index, parity, gestational age, amount of bleeding and randomising centre. The primary outcome was failure to pass the gestational sac within 7 days after randomisation. The prespecified key secondary outcome was requirement for surgery to resolve the miscarriage. A within-trial cost-effectiveness study and a nested qualitative study were also conducted. Women who completed the trial protocol were purposively approached to take part in an interview to explore their satisfaction with and the acceptability of medical management of missed miscarriage. <br><strong> Results<br></strong> A total of 711 women, from 28 hospitals in the UK, were randomised to receive either mifepristone plus misoprostol (357 women) or placebo plus misoprostol (354 women). The follow-up rate for the primary outcome was 98% (696 out of 711 women). The risk of failure to pass the gestational sac within 7 days was 17% (59 out of 348 women) in the mifepristone plus misoprostol group, compared with 24% (82 out of 348 women) in the placebo plus misoprostol group (risk ratio 0.73, 95% confidence interval 0.54 to 0.98; p = 0.04). Surgical intervention to resolve the miscarriage was needed in 17% (62 out of 355 women) in the mifepristone plus misoprostol group, compared with 25% (87 out of 353 women) in the placebo plus misoprostol group (risk ratio 0.70, 95% confidence interval 0.52 to 0.94; p = 0.02). There was no evidence of a difference in the incidence of adverse events between the two groups. A total of 42 women, 19 in the mifepristone plus misoprostol group and 23 in the placebo plus misoprostol group, took part in an interview. Women appeared to have a preference for active management of their miscarriage. Overall, when women experienced care that supported their psychological well-being throughout the care pathway, and information was delivered in a skilled and sensitive manner such that women felt informed and in control, they were more likely to express satisfaction with medical management. The use of mifepristone and misoprostol showed an absolute effect difference of 6.6% (95% confidence interval 0.7% to 12.5%). The average cost per woman was lower in the mifepristone plus misoprostol group, with a cost saving of £182 (95% confidence interval £26 to £338). Therefore, the use of mifepristone and misoprostol for the medical management of a missed miscarriage dominated the use of misoprostol alone. <br><strong> Limitations<br></strong> The results from this trial are not generalisable to women diagnosed with incomplete miscarriage and the study does not allow for a comparison with expectant or surgical management of miscarriage. <br><strong> Future work<br></strong> Future work should use existing data to assess and rank the relative clinical effectiveness and safety profiles for all methods of management of miscarriage. <br><strong> Conclusions<br></strong> Our trial showed that pre-treatment with mifepristone followed by misoprostol resulted in a higher rate of resolution of missed miscarriage than misoprostol treatment alone. Women were largely satisfied with medical management of missed miscarriage and would choose it again. The mifepristone and misoprostol intervention was shown to be cost-effective in comparison to misoprostol alone. <br><strong> Trial registration<br></strong> Current Controlled Trials ISRCTN17405024. <br><strong> Funding<br></strong> This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 68. See the NIHR Journals Library website for further project information.
first_indexed 2024-03-06T19:01:21Z
format Journal article
id oxford-uuid:13a1d72d-07dc-4b3a-b8ab-f19f33b8f9f4
institution University of Oxford
language English
last_indexed 2024-03-06T19:01:21Z
publishDate 2021
publisher NIHR Journals Library
record_format dspace
spelling oxford-uuid:13a1d72d-07dc-4b3a-b8ab-f19f33b8f9f42022-03-26T10:15:11ZMifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCTJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:13a1d72d-07dc-4b3a-b8ab-f19f33b8f9f4EnglishSymplectic ElementsNIHR Journals Library2021Devall, AChu, JBeeson, LHardy, PCheed, VSun, YRoberts, TOgwulu, COWilliams, EJones, LPapadopoulos, JLFBender-Atik, RBrewin, JHinshaw, KChoudhary, MAhmed, ANaftalin, JNunes, NOliver, AIzzat, FBhatia, KHassan, IJeve, YHamilton, JDeb, SBottomley, CRoss, JWatkins, LUnderwood, MCheong, YKumar, CGupta, PSmall, RPringle, SHodge, FShahid, AGallos, IHorne, AQuenby, SCoomarasamy, A<strong>Trial design<br></strong> A randomised, parallel-group, double-blind, placebo-controlled multicentre study with health economic and nested qualitative studies to determine if mifepristone (Mifegyne®, Exelgyn, Paris, France) plus misoprostol is superior to misoprostol alone for the resolution of missed miscarriage. <br><strong> Methods<br></strong> Women diagnosed with missed miscarriage in the first 14 weeks of pregnancy were randomly assigned (1 : 1 ratio) to receive 200 mg of oral mifepristone or matched placebo, followed by 800 μg of misoprostol 2 days later. A web-based randomisation system allocated the women to the two groups, with minimisation for age, body mass index, parity, gestational age, amount of bleeding and randomising centre. The primary outcome was failure to pass the gestational sac within 7 days after randomisation. The prespecified key secondary outcome was requirement for surgery to resolve the miscarriage. A within-trial cost-effectiveness study and a nested qualitative study were also conducted. Women who completed the trial protocol were purposively approached to take part in an interview to explore their satisfaction with and the acceptability of medical management of missed miscarriage. <br><strong> Results<br></strong> A total of 711 women, from 28 hospitals in the UK, were randomised to receive either mifepristone plus misoprostol (357 women) or placebo plus misoprostol (354 women). The follow-up rate for the primary outcome was 98% (696 out of 711 women). The risk of failure to pass the gestational sac within 7 days was 17% (59 out of 348 women) in the mifepristone plus misoprostol group, compared with 24% (82 out of 348 women) in the placebo plus misoprostol group (risk ratio 0.73, 95% confidence interval 0.54 to 0.98; p = 0.04). Surgical intervention to resolve the miscarriage was needed in 17% (62 out of 355 women) in the mifepristone plus misoprostol group, compared with 25% (87 out of 353 women) in the placebo plus misoprostol group (risk ratio 0.70, 95% confidence interval 0.52 to 0.94; p = 0.02). There was no evidence of a difference in the incidence of adverse events between the two groups. A total of 42 women, 19 in the mifepristone plus misoprostol group and 23 in the placebo plus misoprostol group, took part in an interview. Women appeared to have a preference for active management of their miscarriage. Overall, when women experienced care that supported their psychological well-being throughout the care pathway, and information was delivered in a skilled and sensitive manner such that women felt informed and in control, they were more likely to express satisfaction with medical management. The use of mifepristone and misoprostol showed an absolute effect difference of 6.6% (95% confidence interval 0.7% to 12.5%). The average cost per woman was lower in the mifepristone plus misoprostol group, with a cost saving of £182 (95% confidence interval £26 to £338). Therefore, the use of mifepristone and misoprostol for the medical management of a missed miscarriage dominated the use of misoprostol alone. <br><strong> Limitations<br></strong> The results from this trial are not generalisable to women diagnosed with incomplete miscarriage and the study does not allow for a comparison with expectant or surgical management of miscarriage. <br><strong> Future work<br></strong> Future work should use existing data to assess and rank the relative clinical effectiveness and safety profiles for all methods of management of miscarriage. <br><strong> Conclusions<br></strong> Our trial showed that pre-treatment with mifepristone followed by misoprostol resulted in a higher rate of resolution of missed miscarriage than misoprostol treatment alone. Women were largely satisfied with medical management of missed miscarriage and would choose it again. The mifepristone and misoprostol intervention was shown to be cost-effective in comparison to misoprostol alone. <br><strong> Trial registration<br></strong> Current Controlled Trials ISRCTN17405024. <br><strong> Funding<br></strong> This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 68. See the NIHR Journals Library website for further project information.
spellingShingle Devall, A
Chu, J
Beeson, L
Hardy, P
Cheed, V
Sun, Y
Roberts, T
Ogwulu, CO
Williams, E
Jones, L
Papadopoulos, JLF
Bender-Atik, R
Brewin, J
Hinshaw, K
Choudhary, M
Ahmed, A
Naftalin, J
Nunes, N
Oliver, A
Izzat, F
Bhatia, K
Hassan, I
Jeve, Y
Hamilton, J
Deb, S
Bottomley, C
Ross, J
Watkins, L
Underwood, M
Cheong, Y
Kumar, C
Gupta, P
Small, R
Pringle, S
Hodge, F
Shahid, A
Gallos, I
Horne, A
Quenby, S
Coomarasamy, A
Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT
title Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT
title_full Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT
title_fullStr Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT
title_full_unstemmed Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT
title_short Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT
title_sort mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage the mifemiso rct
work_keys_str_mv AT devalla mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT chuj mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT beesonl mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT hardyp mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT cheedv mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT suny mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT robertst mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT ogwuluco mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT williamse mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT jonesl mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT papadopoulosjlf mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT benderatikr mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT brewinj mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT hinshawk mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT choudharym mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT ahmeda mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT naftalinj mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT nunesn mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT olivera mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT izzatf mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT bhatiak mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT hassani mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT jevey mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT hamiltonj mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT debs mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT bottomleyc mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT rossj mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT watkinsl mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT underwoodm mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT cheongy mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT kumarc mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT guptap mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT smallr mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT pringles mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT hodgef mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT shahida mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT gallosi mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT hornea mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT quenbys mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct
AT coomarasamya mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct